RoundAngle Advisors LLC Takes $1.70 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

RoundAngle Advisors LLC acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 198,456 shares of the biopharmaceutical company’s stock, valued at approximately $1,695,000. Ocular Therapeutix comprises approximately 1.6% of RoundAngle Advisors LLC’s holdings, making the stock its 25th biggest position. RoundAngle Advisors LLC owned 0.13% of Ocular Therapeutix at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Amalgamated Bank grew its stake in shares of Ocular Therapeutix by 37.9% during the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 1,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Ocular Therapeutix by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 1,015 shares during the last quarter. Algert Global LLC acquired a new position in Ocular Therapeutix in the 2nd quarter worth about $69,000. Capital Performance Advisors LLP bought a new position in Ocular Therapeutix in the third quarter valued at about $70,000. Finally, Diversified Trust Co acquired a new stake in shares of Ocular Therapeutix during the third quarter valued at about $106,000. 59.21% of the stock is owned by institutional investors and hedge funds.

Ocular Therapeutix Trading Down 0.5 %

NASDAQ:OCUL opened at $8.01 on Monday. Ocular Therapeutix, Inc. has a 52 week low of $3.76 and a 52 week high of $11.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The firm’s fifty day moving average is $9.00 and its 200-day moving average is $8.99. The firm has a market cap of $1.26 billion, a P/E ratio of -6.07 and a beta of 1.23.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the transaction, the insider now directly owns 269,059 shares in the company, valued at approximately $2,424,221.59. This represents a 1.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on OCUL. Scotiabank started coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.71.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.